831 related articles for article (PubMed ID: 18641636)
1. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.
Junutula JR; Raab H; Clark S; Bhakta S; Leipold DD; Weir S; Chen Y; Simpson M; Tsai SP; Dennis MS; Lu Y; Meng YG; Ng C; Yang J; Lee CC; Duenas E; Gorrell J; Katta V; Kim A; McDorman K; Flagella K; Venook R; Ross S; Spencer SD; Lee Wong W; Lowman HB; Vandlen R; Sliwkowski MX; Scheller RH; Polakis P; Mallet W
Nat Biotechnol; 2008 Aug; 26(8):925-32. PubMed ID: 18641636
[TBL] [Abstract][Full Text] [Related]
2. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
Chen Y; Clark S; Wong T; Chen Y; Chen Y; Dennis MS; Luis E; Zhong F; Bheddah S; Koeppen H; Gogineni A; Ross S; Polakis P; Mallet W
Cancer Res; 2007 May; 67(10):4924-32. PubMed ID: 17510422
[TBL] [Abstract][Full Text] [Related]
3. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
[TBL] [Abstract][Full Text] [Related]
4. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates ace the tolerability test.
Damle NK
Nat Biotechnol; 2008 Aug; 26(8):884-5. PubMed ID: 18688241
[No Abstract] [Full Text] [Related]
6. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
7. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
[TBL] [Abstract][Full Text] [Related]
8. The pharmacologic basis for antibody-auristatin conjugate activity.
Alley SC; Zhang X; Okeley NM; Anderson M; Law CL; Senter PD; Benjamin DR
J Pharmacol Exp Ther; 2009 Sep; 330(3):932-8. PubMed ID: 19498104
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation through biomarker analysis--a toxicity study in the cynomolgus monkey using an antibody-cytotoxic conjugate against ovarian cancer.
Hsieh FY; Tengstrand E; Lee JW; Li LY; Silverman L; Riordan B; Miwa G; Milton M; Alden C; Lee F
Toxicol Appl Pharmacol; 2007 Oct; 224(1):12-8. PubMed ID: 17681578
[TBL] [Abstract][Full Text] [Related]
10. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
11. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
12. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
13. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry.
Xu K; Liu L; Saad OM; Baudys J; Williams L; Leipold D; Shen B; Raab H; Junutula JR; Kim A; Kaur S
Anal Biochem; 2011 May; 412(1):56-66. PubMed ID: 21216214
[TBL] [Abstract][Full Text] [Related]
14. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.
Jeffrey SC; Andreyka JB; Bernhardt SX; Kissler KM; Kline T; Lenox JS; Moser RF; Nguyen MT; Okeley NM; Stone IJ; Zhang X; Senter PD
Bioconjug Chem; 2006; 17(3):831-40. PubMed ID: 16704224
[TBL] [Abstract][Full Text] [Related]
15. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract][Full Text] [Related]
17. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
Pimm MV
Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
[TBL] [Abstract][Full Text] [Related]
18. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
19. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
20. Site-Specific Conjugation of Thiol-Reactive Cytotoxic Agents to Nonnative Cysteines of Engineered Monoclonal Antibodies.
Dickgiesser S; Kellner R; Kolmar H; Rasche N
Methods Mol Biol; 2019; 2033():1-14. PubMed ID: 31332743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
